Research to Restore
At 16, our son, Sam, experienced symptoms of double vision that led to a diagnosis of Multiple Sclerosis (MS). For 2 years, he medicated himself with a weekly injection of a drug designed to halt the attack of lesions on his brain. However, this treatment was not successful in stopping the development of new brain lesions.
More than 2.3 million people worldwide have MS. Most treatments on the market attempt to modify and suppress the immune system from further lesion formation within the Central Nervous System.
An exciting, new investigation at The Cleveland Clinic Mellen Center Neurological Institute, led by Jeffrey Cohen, MD, is looking an FDA-approved drug already on the market. It has been identified recently as an agent which may activate cells in the brain to remyelinate (repair the myelin) and white matter already damaged by MS.
When used with mice models, the drug was effective in enhancing myelination and reversing paralysis.
Dr. Cohen and researchers need this seed funding to begin conducting clinical trials with MS patients. After initial trials show promise, additional funds can be applied for through government grants, the MS Society and other Cleveland Clinic sources.
Already approved by the FDA, this drugs would quickly be available for widespread use following successful trials. Please consider being a seed donor and help us champion this effort to repair what has been lost by many MS patients.